📝 SummarXiv

Abstract

The COVID-19 pandemic prompted a surge in computational models to simulate disease dynamics and guide interventions. Agent-based models (ABMs) are well-suited to capture population and environmental heterogeneity, but their rapid deployment raised questions about utility for health policy. We systematically reviewed 536 COVID-19 ABM studies published from January 2020 to December 2023, retrieved from Web of Science, PubMed, and Wiley on January 30, 2024. Studies were included if they used ABMs to simulate COVID-19 transmission, where reviews were excluded. Studies were assessed against nine criteria of model usefulness, including transparency and re-use, interdisciplinary collaboration and stakeholder engagement, and evaluation practices. Publications peaked in late 2021 and were concentrated in a few countries. Most models explored behavioral or policy interventions (n = 294, 54.85%) rather than real-time forecasting (n = 9, 1.68%). While most described model assumptions (n = 491, 91.60%), fewer disclosed limitations (n = 349, 65.11%), shared code (n = 219, 40.86%), or built on existing models (n = 195, 36.38%). Standardized reporting protocols (n = 36, 6.72%) and stakeholder engagement were rare (13.62%, n = 73). Only 2.24% (n = 12) described a comprehensive validation framework, though uncertainty was often quantified (n = 407, 75.93%). Limitations of this review include underrepresentation of non-English studies, subjective data extraction, variability in study quality, and limited generalizability. Overall, COVID-19 ABMs advanced quickly, but lacked transparency, accessibility, and participatory engagement. Stronger standards are needed for ABMs to serve as reliable decision-support tools in future public health crises.